Neurosense Therapeutics Ltd expected to post breakeven results a share - Earnings Preview
Neurosense Therapeutics Ltd <NRSN.OQ> expected to post breakeven results a share - Earnings Preview
Neurosense Therapeutics Ltd NRSN.OQ NRSN.O is expected to report resultson July 30 (estimated) for the period ending March 31 2026
LSEG's mean analyst estimate for Neurosense Therapeutics Ltd is for breakeven results per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Neurosense Therapeutics Ltd is $7.50, about 1,177.7% above its last closing price of $0.59
This summary was machine generated July 28 at 11:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)